Appendix 1 - Clinical Trial Access QPI Development Process
Preparatory Work and Scoping
The National Cancer QPI Development Programme commenced in May 2010. At the outset, it was apparent that various issues were common to all cancer types. These areas were agreed by the National Cancer Quality Steering Group ( NCQSG) to be: Multi-Disciplinary Team Meeting; Clinical Trial Access; and Patient Experience.
A generic QPI regarding Clinical Trial Access was developed by the NCQSG, based upon the NHS Quality Improvement Scotland Standards for the Management of Core Cancer Services 3, published in 2008. Following discussion at the NCQSG, further development and consultation was undertaken, principally with the Scottish Cancer Research Networks.
The Clinical Trials short life working group ( SLWG) defined an evidence based, measurable indicator with a clear focus on improving the quality and outcome of care provided.
The following criteria was utilised when developing the QPI:
- Overall importance - does the indicator address an area of clinical importance that would significantly impact on the quality and outcome of care delivered?
- Evidence based - is the indicator based on high quality clinical evidence?
- Measurability - is the indicator measurable, that is, are there explicit requirements
for data measurement and are the required data items accessible and available fora
The Clinical Trial Access QPI was included as part of the Clinical Trial Quality Performance Indicator Engagement Document which was made available on the Scottish Government website in January 2014, as part of a wide clinical and public engagement exercise.
During the engagement period clinical and management colleagues from across NHSScotland, patients and the wider public were given the opportunity to influence the development of the Clinical Trial Access QPI. Several different methods of engagement were utilised:
Professional groups, health service staff, voluntary organisations and individuals:
- Wide circulation of the draft documentation for comment and feedback.
Patient representative groups:
- Organised patient focus group sessions were held.
Following the engagement period all comments and responses received were reviewed by the SLWG and used to produce and refine the final indicator.
Email: Chris Booth, email@example.com
Phone: 0300 244 4000 – Central Enquiry Unit
The Scottish Government
St Andrew's House